Matthew Plaud, chief operating officer of IntegriCell at Cryoport Systems, has argued that the real test for advanced therapy supply chains comes not in the clinic, but when programmes begin to move towards commercial scale.
In a conversation with Contract Pharma, Plaud said the systems that can support a therapy through early development are often not robust enough to withstand rising patient volumes. At that point, small inefficiencies stop being manageable and start multiply...
Continue Reading This Article
Enjoy this article as well as all of our content, including reports, news, tips and more.
By registering or signing into your SRM Today account, you agree to SRM Today's Terms of Use and consent to the processing of your personal information as described in our Privacy Policy.
ing, while variability becomes harder to contain.
His central point is that the problem is not simply one of logistics. It is, he suggests, a design issue. Too many supply chains are assembled around individual milestones without enough thought given to how those decisions will hold together over time. As therapies progress from early trials to wider rollout, that fragmented approach can leave sponsors dealing with avoidable complexity and weaker resilience.
Plaud also stressed the growing demand for visibility across the chain. For patient-specific therapies, he said, teams need documentation that is complete, auditable and capable of showing exactly where materials have been and what conditions they have experienced. Reliance on disconnected systems, he warned, creates unnecessary risk.
That view aligns with Cryoport Systems’ wider messaging on advanced therapy manufacturing, where the company has repeatedly pushed the case for more integrated operations. In other materials, it has argued that fragmented vendor networks, siloed data and limited end-to-end oversight can all undermine efficiency, product integrity and regulatory compliance.
Cryoport has also positioned its own platform around that idea, describing services that span cryopreservation, biostorage, packaging, labelling, regulatory support and direct-to-site distribution. The company says such integration is essential if cell and gene therapy supply chains are to remain consistent and scalable as therapies move through the full lifecycle.
The broader message is that commercial success in advanced therapies will depend not just on scientific progress, but on supply chains built to absorb complexity rather than break under it.
Source: Noah Wire Services
